Relationship Will Allow More Cancer Patients to Benefit from ProTom’s Proton Therapy

ProTom International, a provider of compact proton therapy technology for cancer treatment, has entered into an agreement with the Behnke Group, a Texas-based healthcare consulting firm. The relationship will enhance ProTom’s expansion of U.S. markets through connections with the Behnke Group’s network in the industry, allowing a greater number of cancer patients to benefit from ProTom’s proton therapy treatments.

Proton therapy is an advanced form of radiation treatment that uses protons to treat cancer.

“We’re confident that the Behnke Group’s extensive expertise will be a valuable asset in expanding our U.S. market, enabling us to provide our life-saving proton therapies to as many patients as possible,” said Stephen Spotts, ProTom International co-founder and CEO.